We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

272 hedge funds and large institutions have $3.92B invested in Protagonist Therapeutics in 2025 Q2 according to their latest regulatory filings, with 50 funds opening new positions, 120 increasing their positions, 76 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

58% more repeat investments, than reductions

Existing positions increased: 120 | Existing positions reduced: 76

25% more capital invested

Capital invested by funds: $3.15B → $3.92B (+$773M)

8.04% more ownership

Funds ownership: 106.46% → 114.5% (+8%)

2% more first-time investments, than exits

New positions opened: 50 | Existing positions closed: 49

0% more funds holding in top 10

Funds holding in top 10: 14 → 14 (0)

1% less funds holding

Funds holding: 275 → 272 (-3)

12% less call options, than puts

Call options by funds: $18.4M | Put options by funds: $20.8M

Holders
272
Holders Change
-3
Holders Change %
-1.09%
% of All Funds
3.58%
Holding in Top 10
14
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.18%
New
50
Increased
120
Reduced
76
Closed
49
Calls
$18.4M
Puts
$20.8M
Net Calls
-$2.39M
Net Calls Change
-$21.6M

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$103M
2
CC
Commodore Capital
New York
+$51.6M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$35.9M
4
BI
BVF Inc
California
+$30.5M
5
Holocene Advisors
Holocene Advisors
New York
+$25.5M

Top Sellers

Rank Fund Capital Flow
1
Focus Partners Wealth
Focus Partners Wealth
Massachusetts
-$21M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$18.5M
3
NVCHI
New Vernon Capital Holdings II
New Jersey
-$16.4M
4
AGP
Artia Global Partners
Florida
-$14.9M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
-$13.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
26
Invesco
Georgia
$39.9M -$6.62M -137,968 -16%
Northern Trust
27
Northern Trust
Illinois
$34M -$1.17M -24,441 -4%
Charles Schwab
28
Charles Schwab
California
$31.8M +$847K +17,646 +3%
Fidelity Investments
29
Fidelity Investments
Massachusetts
$29.8M +$2.88M +60,089 +13%
Holocene Advisors
30
Holocene Advisors
New York
$29.3M +$25.5M +530,326 New
Janus Henderson Group
31
Janus Henderson Group
United Kingdom
$24.7M +$20.4M +425,374 +1,983%
BNP Paribas Asset Management
32
BNP Paribas Asset Management
France
$24.7M +$3.19M +66,377 +17%
JP Morgan Chase
33
JP Morgan Chase
New York
$24.6M -$1.11M -23,207 -5%
Toronto Dominion Bank
34
Toronto Dominion Bank
Ontario, Canada
$24.6M – – –
6CM
35
683 Capital Management
New York
$24.6M -$2.64M -55,000 -11%
AAA
36
Affinity Asset Advisors
New York
$24.3M +$1.92M +40,000 +10%
JAM
37
Jupiter Asset Management
United Kingdom
$22.4M +$11.4M +237,581 +141%
MP
38
Mangrove Partners
Connecticut
$21.9M – – –
Bank of New York Mellon
39
Bank of New York Mellon
New York
$21.4M +$538K +11,219 +3%
Principal Financial Group
40
Principal Financial Group
Iowa
$18.2M -$814K -16,961 -5%
Raymond James Financial
41
Raymond James Financial
Florida
$17.2M +$632K +13,159 +4%
VOYA Investment Management
42
VOYA Investment Management
Georgia
$15.5M +$10.6M +220,676 +370%
EP
43
Eversept Partners
New York
$15.3M -$12.9M -269,800 -49%
UBS AM
44
UBS AM
Illinois
$13.5M +$1.66M +34,617 +17%
Barclays
45
Barclays
United Kingdom
$11.7M +$4.83M +100,680 +90%
Public Sector Pension Investment Board (PSP Investments)
46
Public Sector Pension Investment Board (PSP Investments)
Quebec, Canada
$11.7M +$1.07M +22,250 +12%
Dimensional Fund Advisors
47
Dimensional Fund Advisors
Texas
$9.95M +$2.81M +58,496 +48%
Renaissance Technologies
48
Renaissance Technologies
New York
$9.57M -$7.22M -150,433 -46%
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$9.56M +$526K +10,963 +7%
MAP
50
Moody Aldrich Partners
Massachusetts
$9.43M +$340K +7,087 +4%
1
2
3 4 5

PTGX Hedge Fund Activity: Q2 2025 in Review

272 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2025, worth a combined $3.92B — up 25% from $3.15B a quarter earlier.

Buyers outnumbered sellers: 50 funds opened new PTGX positions and 49 closed out — a net gain of 1 holder — while 120 added to existing stakes and 76 trimmed.

The largest buyer was UBS Group, adding an estimated $103M. The largest seller was Focus Partners Wealth, exiting entirely with an estimated $21M sold.

  • 272 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2025, down from 275 in Q1 2025.
  • Funds reported $3.92B of Protagonist Therapeutics stock for Q2 2025, up 25% quarter-over-quarter.
  • 50 funds opened new Protagonist Therapeutics positions in Q2 2025 and 49 closed out, a net change of +1 holder.
  • The largest Protagonist Therapeutics buyer in Q2 2025 was UBS Group, an estimated $103M added.
  • The largest Protagonist Therapeutics seller in Q2 2025 was Focus Partners Wealth, an estimated $21M sold.

Based on aggregated 13F filings for Q2 2025.